Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Clinical trial NCT05892614 · RECRUITING
Trial details
- NCT number
- NCT05892614
- Sponsor
- aTyr Pharma, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-26
- Primary completion
- 2026-04-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.